Shadi Ziaie

Shadi Ziaie

Auto-generated profile, based on publicly available information

Shadi Ziaie

Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2014 in BMC Neurology
Verified
Journal Article
Open access
PDF file
SJSoodeh Razeghi jahromi
Soodeh Razeghi jahromi
MSMohammad Ali Sahraian
Mohammad Ali Sahraian
FAFereshteh Ashtari
Fereshteh Ashtari
HAHormoz Ayromlou
Hormoz Ayromlou
MEMassoud Etemadifar
Massoud Etemadifar
SZShadi Ziaie
Shadi Ziaie
Month-long daytime Ramadan fasting pose s major challenges to multiple sclerosis (MS) patients in Muslim countries. Physicians should have practical knowledge on the implications of fasting on MS. We present a summary of database searches (Cochrane Database of Systematic Reviews, PubMed) and a mini-symposium on Ramadan fasting and MS. In this symposium, we aimed to review the effect of fasting on MS and suggest practical guidelines on management.

11 July 2020 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
MRMaryam Ghaffari Rahbar
Maryam Ghaffari Rahbar
MNMohsen Nafar
Mohsen Nafar
AKAlireza Khoshdel
Alireza Khoshdel
NDNooshin Dalili
Nooshin Dalili
AAAlireza Abrishami
Alireza Abrishami
SSShiva Samavat
Shiva Samavat

7 November 2022 in Jundishapur Journal of Microbiology
Verified
Journal Article
Open access
PDF file
RTRamin Tolouian
Ramin Tolouian
OMOmid Moradi
Omid Moradi
ZMZuber D. Mulla
Zuber D. Mulla
SZShadi Ziaie
Shadi Ziaie
MHMehrdad Haghighi
Mehrdad Haghighi
MSMohammad Sistanizad
Mohammad Sistanizad
Background: Limited medications are available for post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) infection. Whether bromhexine can prevent or mitigate symptomatic infection after virus exposure is undetermined. Objectives: We aimed to evaluate bromhexine's effect on preventing COVID-19 after close contact exposure. Methods: A multi-center randomized, double-blind, placebo-controlled clinical trial was conducted on 372 adults (≥ 18 years) who had close contact within four days with a household member with confirmed COVID-19. They were randomly assigned to receive bromhexine 8 mg (n = 187) or placebo (n = 185) three times a day for two weeks. The primary outcome was the incidence of symptomatic COVID-19. Secondary outcomes included hospitalization or death, confirmed COVID-19 by Polymerase Chain Reaction (PCR) in symptomatic patients, and adverse drug reactions. Results: The incidence of symptomatic COVID-19 was significantly lower in individuals who received bromhexine than in those who received the placebo (16 [8.6%] vs. 34 [18.4%], relative risk = 0.47, P = 0.005). PCR confirmation was reported in 13 (7.0%) and 26 (14.1%) individuals in the bromhexine and placebo groups, respectively (P = 0.025), with a relative risk reduction of 50%. The hospitalization rate, death, and medication side effects did not vary significantly between the bromhexine and placebo arms. Conclusions: Bromhexine is an effective, non-invasive, affordable agent with a low side-effect profile to prevent symptomatic COVID-19. Early use of bromhexine potentially provides another layer of protection; hence, it can play a role in controlling the pandemic.

26 February 2024 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
FPFatemeh Pourrezagholi
Fatemeh Pourrezagholi
HAHossein Amini
Hossein Amini
OMOmid Moradi
Omid Moradi
SZShadi Ziaie
Shadi Ziaie
Background: In this manuscript, we report a case of tacrolimus-associated hepatotoxicity in a kidney transplant recipient. Case presentation: In this case report, a 56 years old Arab male patient who received a kidney transplant presented with icterus, weakness, and lethargy two weeks after transplantation and tacrolimus initiation. In laboratory analysis hyperbilirubinemia and a rise in hepatic enzymes were observed. All possible causes of hepatotoxicity were examined. The panel for infectious causes was negative. Drug-induced liver injury was diagnosed. The patient’s immunosuppressive regimen was changed to a cyclosporine-based regimen and after this change bilirubin and hepatic enzymes decreased and the patient was discharged without signs and symptoms of hepatitis. Conclusion: It seems that the patient’s hyperbilirubinemia was due to tacrolimus, and the patient’s bilirubin decreased after stopping tacrolimus.

1 March 2025 in Infectious Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
SASara Abolghasemi
Sara Abolghasemi
MGMona Ghazi
Mona Ghazi
SZShadi Ziaie
Shadi Ziaie
AMArash Mahboubi
Arash Mahboubi
LGLatif Gachkar
Latif Gachkar
MNMohammad Naeimipoor
Mohammad Naeimipoor
Background: Nasal colonization of Staphylococcus aureus increases the risk of nosocom-ial infections. Therefore, medications that can decolonize this pathogen can help prevent such infec-tions. Objective: Our study aimed to compare the efficacy of povidone-iodine solution with intranasal mupi-rocin ointment in decolonizing S. aureus from the nasal cavity of healthcare workers. Methods: This single-blinded randomized controlled trial was conducted on healthcare workers car-rying S. aureus nasally. After confirming nasal colonization through culture tests, participants were assigned to intervention groups A and B with an allocation ratio of 1:1. Group A received intranasal mupirocin ointment twice daily for five days, while group B received intranasal povidone-iodine so-lution twice daily for five days. After the decolonization period, samples were taken to compare the efficacy of both interventions in decolonizing S. aureus. Results: In this study, 54 healthcare workers with a mean age of 39.37±7.80 years were included, 42.6% and 57.4% of whom were male and female, respectively. They were randomly assigned to each of the intervention groups. After the intervention, individuals who received povidone-iodine had significantly more positive cultures than those who received mupirocin (37.0% vs. 11.1%, P = 0.026). Additionally, factors such as age, gender, wards, and employment duration may affect the efficacy of mupirocin and povidone-iodine in decolonizing S. aureus from the nasal cavity. Conclusion: The study findings revealed that both mupirocin and povidone-iodine were effective in decolonizing S. aureus from nasal carriers. However, mupirocin was more effective compared with povidone-iodine.

19 August 2024 in Clinical Case Reports
Verified
Journal Article
Open access
SRSoheil Roshanzamiri
Soheil Roshanzamiri
SMSeyyedeh Azam Mousavizadeh
Seyyedeh Azam Mousavizadeh
SRSareh Razazzadeh
Sareh Razazzadeh
SZShadi Ziaie
Shadi Ziaie
Key Clinical Message: Acyclovir can cause neurotoxicity and nephrotoxicity, especially in diabetic patients with renal impairment. Consider acyclovir dose adjustment, close monitoring of kidney function, and hemodialysis as a potential therapeutic option in such cases.